Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells

Cancer Letters

Volumn 349, Issue 2, 2014, Pages 144-151

  Chiu, Wei Hsin ^a,b   Chen, Helen Hai Wen ^b   Chang, Jang Yang ^a,c   Luo, Sheng Jie ^a   Li, Chia Ling ^a   Chen, Chia Ling ^a   Su, Wu Chou ^a,b   Lin, Chiou Feng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

CCRT; Ceramide; JNK; NSCLC; Vinorelbine

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; CHLORPROMAZINE; DESIPRAMINE; FUMONISIN B1; NAVELBINE; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; CERAMIDE; GLUCOSYLTRANSFERASE; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; VINBLASTINE;

AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL SYNCHRONIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DYSPHAGIA; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKOPENIA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMORADIOTHERAPY; DRUG EFFECTS; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RETROSPECTIVE STUDY; TUMOR CELL LINE; VERY ELDERLY;

VINCA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; CHEMORADIOTHERAPY; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; LUNG NEOPLASMS; MALE; OXIDATIVE STRESS; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 84901434753     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.005     Document Type: Article

References (40)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Bulzebruck H., Bopp R., Drings P., Bauer E., Krysa S., Probst G., van Kaick G., Muller K.M., Vogt-Moykopf I. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992, 70:1102-1110.
3. Videtic G.M. Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen?. Cleveland Clinic J. Med. 2012, 79, Electronic Suppl 1:eS32-eS37.
4. Provencio M., Isla D., Sanchez A., Cantos B. Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine. J. Thoracic Dis. 2011, 3:197-204.
5. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992, 326:524-530.
6. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 1995, 13:452-458.
7. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 1996, 88:1210-1215.
8. Sause W., Kolesar P., Taylor S.I., Johnson D., Livingston R., Komaki R., Emami B., Curran W., Byhardt R., Dar A.R., Turrisi A. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest 2000, 117:358-364.
9. Seiwert T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat. Clin. Pract. Oncol. 2007, 4:86-100.
10. Onishi H., Kuriyama K., Yamaguchi M., Komiyama T., Tanaka S., Araki T., Nishikawa K., Ishihara H. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003, 40:79-84.
11. Galetta D., Cesario A., Margaritora S., Porziella V., Piraino A., D'Angelillo R.M., Gambacorta M.A., Ramella S., Trodella L., Valente S., Corbo G.M., Macis G., Mule A., Cardaci V., Sterzi S., Granone P., Russo P. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. J. Thorac. Cardiovasc. Surg. 2006, 131:314-321.
12. Ngan V.K., Bellman K., Panda D., Hill B.T., Jordan M.A., Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000, 60:5045-5051.
13. Burris H.A., Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Seminars Oncol. 1994, 21:14-19. discussion 19-20.
14. Candelaria M., Garcia-Arias A., Cetina L., Duenas-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat. Oncol. 2006, 1:15.
15. Harada H., Seto T., Igawa S., Tsuya A., Wada M., Kaira K., Naito T., Hayakawa K., Nishimura T., Masuda N., Yamamoto N. Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). Int. J. Radiat. Oncol., Biol., Phys. 2012, 82:1777-1782.
16. Chiu W.H., Chen H.W., Su W.C. Oral vinorelbine: a better choice for concurrent chemoradiotherapy in stage III non-small cell lung cancer. J. Solid Tumors 2012, 2:4-15.
17. Edelstein M.P., Wolfe L.A., Duch D.S. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Sem. Oncol. 1996, 23:41-47.
18. Fukuoka K., Arioka H., Iwamoto Y., Fukumoto H., Kurokawa H., Ishida T., Tomonari A., Suzuki T., Usuda J., Kanzawa F., Saijo N., Nishio K. Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 2001, 34:451-460.
19. Fukuoka K., Arioka H., Iwamoto Y., Fukumoto H., Kurokawa H., Ishida T., Tomonari A., Suzuki T., Usuda J., Kanzawa F., Kimura H., Saijo N., Nishio K. Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells. Cancer Chemother. Pharmacol. 2002, 49:385-390.
20. Zhang M., Boyer M., Rivory L., Hong A., Clarke S., Stevens G., Fife K. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int. J. Radiat. Oncol., Biol., Phys. 2004, 58:353-360.
21. Simoens C., Lardon F., Pauwels B., De Pooter C.M., Lambrechts H.A., Pattyn G.G., Breillout F., Vermorken J.B. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 2008, 8:65.
22. Chiu W.H., Luo S.J., Chen C.L., Cheng J.H., Hsieh C.Y., Wang C.Y., Huang W.C., Su W.C., Lin C.F. Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochem. Pharmacol. 2012, 83:1159-1171.
23. Schmidt-Ullrich R.K. Molecular targets in radiation oncology. Oncogene 2003, 22:5730-5733.
24. Huang W.C., Chen C.L., Lin Y.S., Lin C.F. Apoptotic sphingolipid ceramide in cancer therapy. J. Lipids 2011, 2011:565316.
25. Hannun Y.A., Obeid L.M. Many ceramides. J. Biol. Chem. 2011, 286:27855-27862.
26. Lin C.F., Chen C.L., Lin Y.S. Ceramide in apoptotic signaling and anticancer therapy. Curr. Med. Chem. 2006, 13:1609-1616.
27. Anderson C.S., Curran W.J. Combined modality therapy for stage III non-small-cell lung cancer. Sem. Radiat. Oncol. 2010, 20:186-191.
28. Beckmann G., Fietkau R., Huber R.M., Kleine P., Schmidt M., Semrau S., Aubert D., Fittipaldo A., Flentje M. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study. Onkologie 2006, 29:137-142.
29. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur. J. Cancer 2009, 45:228-247.
30. Huang W.C., Tsai C.C., Chen C.L., Chen T.Y., Chen Y.P., Lin Y.S., Lu P.J., Lin C.M., Wang S.H., Tsao C.W., Wang C.Y., Cheng Y.L., Hsieh C.Y., Tseng P.C., Lin C.F. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. FASEB J.: Official Publ. Federation Am. Soc. Exp. Biol. 2011, 25:3661-3673.
31. Stone A.A., Chambers T.C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res. 2000, 254:110-119.
32. Stinchcombe T.E., Fried D., Morris D.E., Socinski M.A. Combined modality therapy for stage III non-small cell lung cancer. Oncologist 2006, 11:809-823.
33. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2:222-228.
34. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7:1875-1884.
35. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 2003, 47:383-392.
36. Kurinna S.M., Tsao C.C., Nica A.F., Jiffar T., Ruvolo P.P. Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase. Cancer Res. 2004, 64:7852-7856.
37. Inoshita S., Takeda K., Hatai T., Terada Y., Sano M., Hata J., Umezawa A., Ichijo H. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J. Biol. Chem. 2002, 277:43730-43734.
38. Obeid L.M., Linardic C.M., Karolak L.A., Hannun Y.A. Programmed cell death induced by ceramide. Science 1993, 259:1769-1771.
39. Bose R., Verheij M., Haimovitz-Friedman A., Scotto K., Fuks Z., Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995, 82:405-414.
40. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J.: Official Publ. Federation Am. Soc. Exp. Biol. 2001, 15:719-730.